+214.2%
ARM vs MRNA
+113.0%
+101.1%
-62.1%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 10y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -1.8% | -7.0% | +5.2% | -1.3% |
| 7D | +19.8% | -4.2% | +24.0% | +20.2% |
| 30D | -21.8% | +7.0% | -28.8% | -22.2% |
| 3M | -26.5% | +263.4% | -289.9% | -36.0% |
| 6M | -3.9% | +334.3% | -338.2% | -20.9% |
| YTD | +82.8% | +684.5% | -601.7% | +30.1% |
| 1Y | +34.3% | +766.2% | -731.8% | -7.1% |
| 3Y | +282.2% | +230.3% | +51.9% | +186.1% |
| All | +214.2% | +113.0% | +101.1% | +154.1% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 10y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
10y analysis · Full analysis span regression · 6 months rolling